Urovant Sciences to Announce Topline Results from the EMPOWUR Phase 3 Study of Vibegron in Patients with Overactive Bladder
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Mar 18, 2019--Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercial…
